Clinical Trial Update: Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TRANSKRIP Plus Chemotherapy for recurrent-persistent cervical cancer has been withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• TRANSKRIP Plus Chemotherapy

Snippet

Sponsor: National Institute of Cancerología | Conditions: Cervical Cancer | Phase 3 | Status: WITHDRAWN